相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro
Shunji Imai et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans
Matti K. Itkonen et al.
DRUG METABOLISM AND DISPOSITION (2019)
The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag
Carmela Gnerre et al.
XENOBIOTICA (2018)
Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans
Matti K. Itkonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects
Pierre-Eric Juif et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension
Shirin Bruderer et al.
EXPERT OPINION ON DRUG SAFETY (2017)
The prostacyclin pathway in pulmonary arterial hypertension: a clinical review
R. Del Pozo et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2017)
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects
Shirin Bruderer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment
Priska Kaufmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects
Shirin Bruderer et al.
CLINICAL THERAPEUTICS (2016)
Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
Janne T. Backman et al.
PHARMACOLOGICAL REVIEWS (2016)
Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information
Soo-Jin Kim et al.
DRUG METABOLISM AND DISPOSITION (2016)
Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone
Matti K. Itkonen et al.
DRUG METABOLISM AND DISPOSITION (2016)
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects
Priska Kaufmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study
Daniela Baldoni et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2015)
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Olivier Sitbon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes
Yuji Mukai et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin
Matti K. Itkonen et al.
DRUG METABOLISM AND DISPOSITION (2015)
Pulmonary Arterial Hypertension The Clinical Syndrome
Yen-Chun Lai et al.
CIRCULATION RESEARCH (2014)
Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions
A. Tornio et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects
Shirin Bruderer et al.
PHARMACOLOGY (2014)
Impact of the CYP2C8*3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone
Christina L. Aquilante et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8
Christina L. Aquilante et al.
PHARMACOGENETICS AND GENOMICS (2013)
Investigation of the Pharmacokinetic Interactions of Deferasirox, a Once-Daily Oral Iron Chelator, With Midazolam, Rifampin, and Repaglinide in Healthy Volunteers
Andrej Skerjanec et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Pathology of pulmonary hypertension
Rubin M. Tuder et al.
CLINICS IN CHEST MEDICINE (2007)
Prostacyclin therapy for pulmonary arterial hypertension: New directions
M Gomberg-Maitland et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
The effect of the cytochrome P450CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects
C Martinez et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Prostanoid therapy for pulmonary arterial hypertension
DB Badesch et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A
A Soyama et al.
PHARMACOLOGY & TOXICOLOGY (2002)
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
